RecruitingPhase 2NCT06926595

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

Studying Graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Milton S. Hershey Medical Center
Principal Investigator
Joseph Cioccio, MD
Penn State Cancer Institute
Intervention
Cyclophosphamide (primary intervention for GVHD prophylaxis)(drug)
Enrollment
41 target
Eligibility
18 years · All sexes
Timeline
20262031

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06926595 on ClinicalTrials.gov

Other trials for Graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Graft versus host disease

← Back to all trials